DOCSLIB.ORG

上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02607) 2019 ANNUAL RESULTS ANNOUNCEMENT The board of directors (the “Board”) of Shanghai Pharmaceuticals Holding Co., Ltd. (the “Company”) is pleased to announce the results of the Company and its subsidiaries (collectively the “Group”) for the year ended 31 December 2019. These annual results are prepared in accordance with the Hong Kong Financial Reporting Standards and audited by PricewaterhouseCoopers. The Audit Committee of the Board has reviewed these annual results. The full content of the Company’s annual report of 2019 is attached to this announcement. The formal annual report will be dispatched to the shareholders of the Company and published on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.sphchina.com) at an appropriate time. By Order of the Board Shanghai Pharmaceuticals Holding Co., Ltd.* ZHOU Jun Chairman Shanghai, the PRC, 28 March 2020 As at the date of this announcement, the executive Directors are Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo; the non-executive Directors are Mr. ZHOU Jun, Mr. GE Dawei and Ms. LI An; and the independent non-executive Directors are Mr. CAI Jiangnan, Mr. HONG Liang, Mr. GU Zhaoyang and Mr. Manson FOK. * For identification purpose only OUR VISION Become a respectful manufacturer with leading brand medicine and a service provider in healthcare field with industry reputation OUR MISSION Perseverance, committed to enhancing people’s healthy living quality OUR CORE VALUES Innovation, integrity, cooperation, tolerance, responsibility Contents Chapter 1 Definitions 2 Chapter 2 Corporate Information 6 Chapter 3 Financial Highlights 8 Chapter 4 Chairman’s Statement 9 Chapter 5 Management Discussion and Analysis 15 Chapter 6 Report of the Board of Directors 40 Chapter 7 Directors, Supervisors and Senior Management 67 Chapter 8 Corporate Governance Report 81 Chapter 9 Independent Auditor’s Report 89 Definitions In this report, unless the context otherwise requires, the following terms shall have the following meanings: Definitions of Common Terms “the Group”, “Group”, Shanghai Pharmaceuticals Holding Co., Ltd. (上海醫藥集團股份有限公司), “the Company”, “Company” or a joint stock company incorporated in the PRC with limited liability (shares “Shanghai Pharmaceuticals” of which are listed on the Shanghai Stock Exchange with stock code 601607, and on the Main Board of the Hong Kong Stock Exchange with stock code 02607) or Shanghai Pharmaceuticals Holding Co., Ltd. and its subsidiaries, where applicable “Articles of Association” or the articles of association of Shanghai Pharmaceuticals (as amended “Articles” from time to time) “Reporting Period” the 12-month period from 1 January 2019 to 31 December 2019 “YOY” year-on-year “Shares” shares of Shanghai Pharmaceuticals with a nominal value of RMB1.00 each, comprising both A Shares and H Shares “A Shares” domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed on the Shanghai Stock Exchange and traded in RMB “H Shares” overseas shares of the Company, with a nominal value of RMB1.00 each, which are listed on the Hong Kong Stock Exchange and traded in Hong Kong dollars “RMB” or “Renminbi” Renminbi, the lawful currency of the PRC “HK$” or “HK dollars” or Hong Kong dollars, the lawful currency of Hong Kong “Hong Kong dollars” “US$” US dollars, the lawful currency of the United States of America “AUD” Australian dollars, the lawful currency of Australia “NZ$” New Zealand dollars, the lawful currency of New Zealand “PRC” or “China” the People’s Republic of China; unless the context otherwise requires, references to the PRC or China in this report do not include Hong Kong, Macau or Taiwan “Hong Kong” or “HK” the Hong Kong Special Administrative Region of the PRC 2 Shanghai Pharmaceuticals Holding Co., Ltd. Definitions “Hong Kong Stock Exchange” The Stock Exchange of Hong Kong Limited “Hong Kong Listing Rules” the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended, supplemented or otherwise modified from time to time) “Model Code” the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Hong Kong Listing Rules (as amended, supplemented or otherwise modified from time to time) “Corporate Governance Code” the Corporate Governance Code as set out in Appendix 14 to the Hong Kong Listing Rules (as amended, supplemented or otherwise modified from time to time) “SFO” the Securities and Futures Ordinance, Chapter 571, Laws of Hong Kong, as amended from time to time “Controlling Shareholders” unless otherwise stated, has the meaning ascribed to it under the Hong Kong Listing Rules, including SIIC, Shanghai Shangshi and Shanghai Pharmaceutical (Group) “WHO” World Health Organization “FDA” Food and Drug Administration of the United States “MOF” Ministry of Finance of the People’s Republic of China “NMPA” National Medical Products Administration of the People’s Republic of China (中華人民共和國國家藥品監督管理局) “NHSA” National Healthcare Security Administration of the People’s Republic of China (中華人民共和國國家醫療保障局) “CDE” Center For Drug Evaluation of NMPA (中華人民共和國國家藥品監督管理 局藥品評審中心) “CSRC“ China Securities Regulatory Commission (中國證券監督管理委員會) “Shanghai SASAC” Shanghai State-owned Assets Supervision and Administration Commission (上海市國有資產監督管理委員會) “NHC” National Health Commission of the People’s Republic of China (中華人 民共和國國家衛生健康委員會) Annual Report 2019 3 Definitions “SIIC” Shanghai Industrial Investment (Holdings) Co., Ltd. (上海實業（集團）有限 公司) “Shanghai Shangshi” Shanghai Shangshi (Group) Co., Ltd. (上海上實（集團）有限公司) “Shanghai Pharmaceutical (Group)” Shanghai Pharmaceutical (Group) Co., Ltd. (上海醫藥（集團）有限公司) “Shanghai Guosheng” Shanghai Guosheng Group Co., Ltd. (上海國盛（集團）有限公司) “Shanghai Shengrui” Shanghai Shengrui Investment Co., Ltd. (上海盛睿投資有限公司) “Shenergy Group” Shenergy (Group) Co., Ltd. (申能（集團）有限公司) “HISUN“ Zhejiang Hisun Pharmaceutical Co., Ltd. “NCPC“ North China Pharmaceutical Company Ltd “HPGC“ Harbin Pharmaceutical Group Co., Ltd. “MediTrust Health“ Shanghai MediTrust Health Co., Ltd. (上海鎂信健康科技有限公司) “Cardinal Health” Cardinal Health (Shanghai) Pharmaceutical Co., Ltd. (上藥康得樂（上海） 醫藥有限公司) “Liaoning Foreign Trading” Liaoning Medical Foreign Trading Co., Ltd. (遼寧省醫藥對外貿易有限 公司) “Sichuan Guojia” Sichuan Guojia Pharmaceutical Science & Technology Co., Ltd. (四川省 國嘉醫藥科技有限責任公司) “China Isotope & Radiation” China Isotope & Radiation Corporation (中國同輻股份有限公司) “Hansoh Pharmaceutical” Hansoh Pharmaceutical Group Company Limited (翰森製藥集團) “Lumosa Therapeutics” Lumosa Therapeutics Co., Ltd. (順天醫藥生技股份有限公司) “Takeda China” Takeda (China) International Trading Co., Ltd. (武田（中國）國際貿易有限 公司) “Astellas” Astellas Pharmaceuticals (China) Co., Ltd. (安斯泰來製藥（中國）有限公司) “Adia“ Adia (Shanghai) Pharmaceuticals Co., Ltd. (埃地亞（上海）醫藥有限公司) “Alembic“ Alembic Pharma, an Indian pharmaceutical company “Oncternal” Oncternal Therapeutics Inc, a medical group from the United States 4 Shanghai Pharmaceuticals Holding Co., Ltd. Definitions “BIOCAD” BIOCAD, a biopharmaceutical company from Russia “4+7” the 11 pilot cities in which the state organized the centralized procurement of drugs with target quantity “Alliance Region(s)” provincial administrative regions participating the centralized procurement of drugs with target quantity organized by the state “Double Hundred Action” the “Double Hundred Action” work plan for state-owned enterprise reform “DTP” Direct To Patient “MES” Manufacturing Execution System “LIMS” Laboratory Information Management System “GMP” Good Manufacturing Practice “GSP” Good Supply Practice “ANDA” the Abbreviated New Drug Application “BE” bioequivalence “IND” investigational new drug “DMF” Drug master file “DRGs” (disease) diagnosis related groups “license-in” introduction of drug license “first-in-class” first new drug target or mechanism of action discovered “best-in-class” best in class in comparison to its peers “BD” expanded introduction of new drugs “PBM” pharmacy benefit management Annual Report 2019 5 Corporate Information DIRECTOR AUTHORISED REPRESENTATIVES Executive Directors Mr. CHO Man Ms. CHEN Jinzhu Mr. CHO Man (President) Mr. LI Yongzhong (Vice President) Mr. SHEN Bo (Vice President and Chief Financial STRATEGY COMMITTEE Officer) Mr. ZHOU Jun (Convener) Non-executive Directors Mr. CAI Jiangnan Mr. Manson FOK Mr. ZHOU Jun (Chairman) Mr. GE Dawei (Vice Chairman) Ms. LI An AUDIT COMMITTEE Mr. GU Zhaoyang (Convener) Independent non-executive Directors Mr. Manson FOK Mr. CAI Jiangnan Mr. HONG Liang Mr. HONG Liang Mr. GU Zhaoyang Mr. Manson FOK NOMINATION COMMITTEE Mr. CAI Jiangman (Convener) SUPERVISORS Mr. CHO Man Mr. HONG Liang Mr. Xu Youli Mr. HUAN Jianchun Mr. Xin Keng REMUNERATION AND ASSESSMENT COMMITTEE JOINT COMPANY SECRETARIES Mr. HONG Liang (Convener) Mr. GE Dawei Ms. CHEN Jinzhu Mr. Gu Zhaoyang Ms. Leung Suet Wing 6 Shanghai Pharmaceuticals Holding Co., Ltd. Corporate Information COMPANY NAME STOCK ABBREVIATION Shanghai Pharmaceuticals Holding Co., Ltd. SH PHARMA REGISTERED ADDRESS STOCK EXCHANGE ON WHICH
Load more

Recommended publications
  • Qingdao Port International Co., Ltd. 青島港國際股份有限公司
    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Qingdao Port International Co., Ltd. 青 島 港 國 際 股 份 有 限 公 司 (A joint stock company established in the People’s Republic of China with limited liability) (Stock Code: 06198) VOLUNTARY ANNOUNCEMENT UPDATE ON THE PHASE III OF OIL PIPELINE PROJECT This is a voluntary announcement made by Qingdao Port International Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”). Reference is made to the voluntary announcement of the Company dated 28 December 2018, in relation to the groundbreaking ceremony for the phase III of the Dongjiakou Port-Weifang-Central and Northern Shandong oil pipeline construction project (the “Phase III of Oil Pipeline Project”). The Phase III of Oil Pipeline Project was put into trial operation on 8 January 2020. As of the date of this announcement, the Dongjiakou Port-Weifang-Central and Northern Shandong oil pipeline has extended to Dongying City in the north, opening the “Golden Channel” of crude oil industry chain from the Yellow Sea to the Bohai Bay. SUMMARY OF THE PHASE III OF OIL PIPELINE PROJECT The Phase III of Oil Pipeline Project is the key project for the transformation of old and new energy in Shandong Province, and the key construction project of the Group.
    [Show full text]
  • An Empirical Analysis of Industrialization Development Based on AHP in Shandong Peninsula City Group
    2015 2nd International Conference on Material Engineering and Application (ICMEA 2015) ISBN: 978-1-60595-323-6 An Empirical Analysis of Industrialization Development Based on AHP in Shandong Peninsula City Group Ning Liu1, Jinghua Sha & Hongyun Ma2 1School of Humanities and Economic Management, China University of Geosciences, Beijing, China 2Key Laboratory of Carrying Capacity Assesssment for Resource and Environment, Ministry of Land & Resources, Beijing, China ABSTRACT: It is very meaningful to evaluate the degree of industrialization in Shandong Peninsula City Group for internal development of the cities group and the construction of new urbanization in China. This study analyzed the industrialization development of Shandong peninsula city group and every city with the method of AHP. The conclusion indicted that the industrialization stage of Shandong peninsula city group is the advanced stage of industrial implementation phase, while the industrialization stage of Shandong province is the primary stage of industrial implementation phase. Jinan and Qingdao have been after industrialization stage, while Zibo, Dongying, Yantai and Weihai have been the advanced stage of industrial implementation phase, and Weifang and Rizhao have been the primary stage of industrial implementation phase. 1 INTRODUCTION Industrialization is defined to be a process that with the continuous development of modern industry, especially the development of manufacturing, the proportion of industrial value accounted for gross domestic product (GDP) keep increasing, and the industry have developed to be the pillar of the economy. World industrialization originated British industrial revolution in the 18th century. Industrialization process with characteristics of mechanized production changed mode of production and way of life, transferring labor, capital and other factors of production from countryside to city, driving the progress of the society.
    [Show full text]
  • Shandong Prepares for Showcase
    CHINA DAILY Friday, July 14, 2017 Shandong special 12 Ancient What they say Editor’s note: A group of Asian Base is looking wisdom media reporters share their insights for a Pakistani on Shandong province during their member and Discover Shandong trip on July 2-8 we will help the inspires in Jinan, Dongying and Yantai. Apart association to from the reporters, we also want to find it in our express our sincere thanks to Talgat country. modern Galimov, photojournalist, Delovoy Shumaila Aslam, reporter, Kazakhstan, Otabek Muratov, The Finance based in Pakistan photojournalist, Jahon Information success Agency based inUzbekistan, Amitha I learnt about Thennakoon, photographer, Ceylon Sun Zi (545- Today based in Sri Lanka, Jirawatt 470 BC), the When emperors of old Ngamsoponsookkoon, producer, great military w o u l d c l i m b Ta i s h a n Nation Multimedia Group, based strategist, Mountain, China’s holiest in Thailand, for their dedication, during my mountain, they’d reach the professionalism and hard working university 1,532-meter peak and kneel spirit during the Asian media’s period and before heaven to pray for a Discover Shandong trip from July obtained in-depth knowledge more fertile land. 2 to 8. in the Sun Zi cultural park set Thousands of years later, up in his hometown Guangrao, I cross into the East China Dongying. It was really a great province of Shandong at We interviewed experience for me! over 300 kilometers per hour Reporters from Asian media outlets capture a fascinating moment of Lyuju Opera, a traditional opera style thriving in several petroleum Gulayim Nurjanova, editor, aboard a state-of-the-art bul- Dongying, Shandong province.
    [Show full text]
  • Land-Use Efficiency in Shandong (China)
    sustainability Article Land-Use Efficiency in Shandong (China): Empirical Analysis Based on a Super-SBM Model Yayuan Pang and Xinjun Wang * Department of Environmental Science and Engineering, Fudan University, Shanghai 200433, China; [email protected] * Correspondence: [email protected] Received: 20 November 2020; Accepted: 14 December 2020; Published: 18 December 2020 Abstract: A reasonable evaluation of land-use efficiency is an important issue in land use and development. By using a super-SBM model, the construction and cultivated land-use efficiency of 17 cities in Shandong from 2006 to 2018 were estimated and the spatial-temporal variation was analyzed. The results showed that: (1) The land use efficiency levels were quite different, and low-efficiency cities impacted the overall development process. (2) The efficiency values of construction land generally fluctuated and rose, meaning that room remains for future efficiency improvements. Cultivated land generally showed a high utilization efficiency, but it fluctuated and decreased. (3) The construction land-use efficiency was highest in the midland region, especially in Laiwu city, followed by the eastern region and Qingdao city, and the western region. The spatial variation in cultivated land presented a trend of “high in the middle, low in the periphery,” centered on Jinan and Yantai city. (4) Pure technical efficiency was the main restriction driving inefficient utilization in the western region, while scale efficiency played that role in the east. Based on the findings, policy suggestions were proposed to improve the land-use efficiency in Shandong and promote urban sustainable development. Keywords: land use; efficiency level; super-SBM model; Shandong Province; construction land; cultivated land 1.
    [Show full text]
  • Annual Report 2020 03 Corporate Information
    Our Vision Dedicate to become a first-tier enterprise in the global mainstream pharmaceutical and healthcare market. Our Mission Better health for families worldwide. 02 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Contents 04 Corporate Information 07 Financial Highlights 08 Chairman’s Statement 12 Management Discussion and Analysis 67 Five-Year Statistics 68 Report of the Directors 91 Supervisory Committee Report 93 Corporate Governance Report 104 Environmental, Social and Governance Report 135 Biographical Details of Directors, Supervisors and Senior Management 144 Independent Auditor’s Report 149 Consolidated Statement of Profit or Loss 150 Consolidated Income Statement 151 Consolidated Statement of Financial Position 153 Consolidated Statement of Changes in Equity 155 Consolidated Statement of Cash Flows 157 Notes to Financial Statements 276 Definitions Annual Report 2020 03 Corporate Information Directors Authorized Representatives Executive Director Mr. Wu Yifang (吳以芳)11 Mr. Wu Yifang (吳以芳) Ms. Kam Mei Ha Wendy (甘美霞) (Chairman1 and Chief Executive Officer) Mr. Chen Qiyu (陳啟宇)12 Non-executive Directors Strategic Committee Mr. Chen Qiyu (陳啟宇)2 Mr. Chen Qiyu (陳啟宇) (Chairman) Mr. Yao Fang (姚方)3 Mr. Wu Yifang (吳以芳) Mr. Xu Xiaoliang (徐曉亮) Mr. Yao Fang (姚方) Mr. Gong Ping (龔平)4 Mr. Xu Xiaoliang (徐曉亮) Mr. Pan Donghui (潘東輝)4 Ms. Li Ling (李玲) Mr. Zhang Houlin (張厚林)5 Mr. Liang Jianfeng (梁劍峰)6 Audit Committee Mr. Wang Can (王燦)7 Ms. Mu Haining (沐海寧)9 Mr. Tang Guliang (湯谷良) (Chairman) Mr. Jiang Xian (江憲) Independent Non-executive Directors Mr. Gong Ping (龔平)4 Mr. Jiang Xian (江憲) Mr. Wang Can (王燦)7 Dr. Wong Tin Yau Kelvin (黃天祐) Ms.
    [Show full text]
  • AMJ Vol 8 No 2 June 2021 Edit.Indd
    63 AMJ. 2021;8(2):63–69 SARS-CoV-2 Transmission and Epidemic Characteristics in Jining City, China Jianwei Zhou,1 Yu Li,2 Cui Kong,3 Jiang Yu,1 Yizhao Li,4 Qinghua Zhang,5 Yao Liang6 1 2 Medical3 Laboratory, Affiliated Hospital of Jining Medical University, Jining City, Shandong Province, China, Medical4 College, Jining Medical University, Jining City, Shandong Province, China, Nursing5 Department, Affiliated Hospital of Jining Medical University, Jining City, Shandong Province, China, Rehabilitation6 Department, Fangan Rehabilitation Hospital of Jinan City, Jinan, China, Neurology Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Health School of Jining City, Jining City, Shandong Province, China Abstract Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that causes severe acute respiratory syndrome has spread to hundreds of countries and infected millions of people, causing Methods:more than a hundred thousand deaths. This study aimed to describe the epidemic characteristics of SARS-CoV-2 and its transmission in a city in China. This was a descriptive study on retrospective data collected from January to February 2020 Results:from reports issued by the authority of Jining City, China, including data on travel history, transmission, gender, and age of infected persons. During the period January and February 2020, 52 cases were confirmed to be SARS-CoV-2 infections with more than half were males (n=32, 61.5%) and and in the age grup of 31–50 yars old (53.8%). The modes of transmission were mostly primary infections (n=23) and a historyth of travel to Conclusions:and from outside of Shandong Province (n=14).
    [Show full text]
  • Annual Report 2012
    (a joint stock limited company incorporated in the People’s Republic of China with limited liability) ANNUAL REPORT 2012 ANNUAL ANNUAL REPORT 2012 Important Notice The Board, Supervisory Committee and the Directors, Supervisors and senior management of the Company warrant the authenticity, accuracy and completeness of the information contained in the annual report and there are no any misrepresentations, misleading statements contained in or material omissions from the annual report for which they shall assume joint and several responsibility. The 2012 Annual Report of Yanzhou Coal Mining Company Limited has been approved by the twelfth meeting of the fifth session of the Board. All 11 directors attended the meeting. The twelfth meeting of the fifth session of the Board of the Company approved the 2012 profit distribution plan, which allowed the Company to distribute an aggregate cash dividends of RMB1.7706 billion (tax inclusive) to the Shareholders, representing a dividend of RMB0.36 per share (tax inclusive). There was no appropriation of funds of the Company by the Controlling Shareholder or its subsidiaries for non-operational activities. There were no guarantees granted to external parties by the Company without complying with the prescribed decision-making procedures. Mr. Li Weimin, Chairman of the Board, Mr. Wu Yuxiang, Chief Financial Officer, and Mr. Zhao Qingchun, Deputy Chief Financial Officer and Head of Accounting Department, hereby warrant the authenticity and completeness of the financial statements contained in this annual report. The forward-looking statements contained in this annual report regarding the Company’s future plans do not constitute any substantive commitment to investors and investors are reminded of investment risks and to exercise caution in their investment.
    [Show full text]
  • LU THAI TEXTILE CO., LTD. ANNUAL REPORT ==2003== Shandong
    LU THAI TEXTILE CO., LTD. ANNUAL REPORT (Adjustment based on International Accounting Standards) ==2003== Shandong · Zibo April 1, 2004 CONTENTS I. IMPORTANT NOTES-----------------------------------------------------------------------------2 II. COMPANY PROFILE----------------------------------------------------------------------------2 III. SUMMARY FINANCIAL HIGHLIGHT AND BUSINESS HIGHLIGHT----------3 IV. CHANGES IN SHARE CAPITAL AND PARTICULARS ABOUT SHAREHOLDERS---------------------------------------------------------------------------5 V. PARTICULARS ABOUT DIRECTORS, SUPERVISORS, SENIOR EXECUTIVES AND EMPLOYEES-----------------------------------------------------------------------------------7 VI. ADMINISTRATIVE STRUCTURE----------------------------------------------------------9 VII. BRIEF OF THE SHAREHOLDERS’ GENERAL MEETING-----------------------10 VIII. REPORT OF BOARD OF DIRECTORS------------------------------------------------11 IX. REPORT OF SUPERVISORY COMMITTEE-------------------------------------------19 X. SIGNIFICANT EVENTS------------------------------------------------------------------------21 XI. FINANCIAL REPORT (ATTACHED)-----------------------------------------------------23 XII. DOCUMENTS AVAILABLE FOR REFERENCE--------------------------------------23 1 I. IMPORTANT NOTES The Board of Directors of Luthai Textile Co., Ltd. (hereinafter referred to as the Company) and its directors hereby confirm that there are no any important omissions, fictitious statements or serious misleading information carried in this report,
    [Show full text]
  • Dongying Statement
    Dongying Statement The Third China Wetlands Cultural Festival and Dongying International Wetland Conservation Conference October 24-25, 2013 The Third China Wetlands Cultural Festival and Dongying International Wetland Conservation Conference was hosted by State Forestry Administration of the Peoples Republic of China and the Peoples Government of Shandong Province on 24-25 October 2013. It was organised by Dongying City Government, Shandong Forestry Department and the Wetlands Conservation and Management Centre of State Forestry Administration. Partners included: Wetlands International, World Wide Fund for Nature, Deutsche Gesellschaft fuer Internationale Zusammenarbeit (GIZ) GmbH, People’s Network, Green China and Hong Kong Star TV. The meeting was attended by 150 participants, including representatives of international organisations including: Secretariat of the Ramsar Convention, United Nations Development Program, Wetlands International, World Wide Fund for Nature, GIZ , Global Environment Centre, Birdlife International, Wildfowl and Wetlands Trust, Conservation International and East Asian – Australasian Flyway Partnership; experts from China, Australia, Germany, Malaysia and the United Kingdom; and a range of representatives from provincial forestry departments, Ramsar Sites, nature reserves and National Wetland Parks from China as well as other sectors. The meeting agreed to the “Dongying Statement” as follows: Wetlands for life Wetlands have strong ecological and production functions, not only for biodiversity and maintaining a balanced ecosystem, but also for the survival of humankind. Wetlands provide clean air, fresh water, food, fibre and other products directly supporting hundreds of millions of people in China and around the world. Maintaining healthy wetlands is a national responsibility related to human welfare and ecosystem security for current and future generations.
    [Show full text]
  • Urban Function Orientation Based on Spatiotemporal Differences and Driving Factors of Urban Construction Land
    Case Study Urban Function Orientation Based on Spatiotemporal Differences and Driving Factors of Urban Construction Land Jintao Li, Ph.D.1; and Zongfeng Sun, Ph.D.2 Abstract: This paper examines the development trends of urban construction land in 17 cities within the Shandong province, China, and uses multivariate linear regression, a geographical detector, and a spatial neighborhood analysis to determine the spatiotemporal driving mechanisms of construction land development from 1985 to 2015. The results reveal clear differences in the scale, rate, direction, and stability of urban construction land, and the 17 cities investigated were divided into four development models, including the uncoordinated wave cities (Jinan, Yantai, and Weifang), uncoordinated stable cities (Zibo, Rizhao, Linyi, Dongying, and Binzhou), coordinated wave cities (Qingdao, Zaozhuang, Taian, Laiwu, Weihai, and Liaocheng), and coordinated stable cities (Jining, Dezhou, and Heze). A number of temporal driving factors affected the expansion scale of urban construction land, including the natural population growth rate, employ- ment index, second industry structure ratio, and firm size index, whereas the spatial driving factors that affected the spatial pattern of urban construction land included the distance to the main railway, distance to the main road, and distance to the city center. Next, points were assigned to different levels of characteristics and spatiotemporal driving factors of the urban construction land, a composite score of urban development was obtained, and the 17 cities were divided into the following zones: core trading (Qingdao), key development (Jinan and Yantai),industrialcluster(Jining,Laiwu,Linyi,Weifang,Weihai,and Zibo), and conserving economic zones (which included the remain- ing eight cities).
    [Show full text]
  • Distribution, Genetic Diversity and Population Structure of Aegilops Tauschii Coss. in Major Whea
    Supplementary materials Title: Distribution, Genetic Diversity and Population Structure of Aegilops tauschii Coss. in Major Wheat Growing Regions in China Table S1. The geographic locations of 192 Aegilops tauschii Coss. populations used in the genetic diversity analysis. Population Location code Qianyuan Village Kongzhongguo Town Yancheng County Luohe City 1 Henan Privince Guandao Village Houzhen Town Liantian County Weinan City Shaanxi 2 Province Bawang Village Gushi Town Linwei County Weinan City Shaanxi Prov- 3 ince Su Village Jinchengban Town Hancheng County Weinan City Shaanxi 4 Province Dongwu Village Wenkou Town Daiyue County Taian City Shandong 5 Privince Shiwu Village Liuwang Town Ningyang County Taian City Shandong 6 Privince Hongmiao Village Chengguan Town Renping County Liaocheng City 7 Shandong Province Xiwang Village Liangjia Town Henjin County Yuncheng City Shanxi 8 Province Xiqu Village Gujiao Town Xinjiang County Yuncheng City Shanxi 9 Province Shishi Village Ganting Town Hongtong County Linfen City Shanxi 10 Province 11 Xin Village Sansi Town Nanhe County Xingtai City Hebei Province Beichangbao Village Caohe Town Xushui County Baoding City Hebei 12 Province Nanguan Village Longyao Town Longyap County Xingtai City Hebei 13 Province Didi Village Longyao Town Longyao County Xingtai City Hebei Prov- 14 ince 15 Beixingzhuang Town Xingtai County Xingtai City Hebei Province Donghan Village Heyang Town Nanhe County Xingtai City Hebei Prov- 16 ince 17 Yan Village Luyi Town Guantao County Handan City Hebei Province Shanqiao Village Liucun Town Yaodu District Linfen City Shanxi Prov- 18 ince Sabxiaoying Village Huqiao Town Hui County Xingxiang City Henan 19 Province 20 Fanzhong Village Gaosi Town Xiangcheng City Henan Province Agriculture 2021, 11, 311.
    [Show full text]
  • Lung Cancer Mortality Clusters in Shandong Province, China: How Do They Change Over 40 Years?
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No.51), pp: 88770-88781 Research Paper Lung cancer mortality clusters in Shandong Province, China: how do they change over 40 years? Zhentao Fu1,*, Yingmei Li2,*, Zilong Lu1,*, Jie Chu1, Jiandong Sun3, Jiyu Zhang1, Gaohui Zhang1, Fuzhong Xue4, Xiaolei Guo1,** and Aiqiang Xu1,** 1Department for Chronic and Non-Communicable Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan, China 2The Second People's Hospital of Jinan, Jinan, China 3School of Public Health and Social Work, Queensland University of Technology, Brisbane, Australia 4School of Public Health, Shandong University, Jinan, China *The first three authors contributed equally to this work **The last two authors contributed equally to this work Correspondence to: Xiaolei Guo, email: [email protected] Aiqiang Xu, email: [email protected] Keywords: lung cancer, spatial scan statistics, mortality, epidemiology Received: March 27, 2017 Accepted: August 06, 2017 Published: September 21, 2017 Copyright: Fu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Lung cancer has long been a major health problem in China. This study aimed to examine the temporal trend and spatial pattern of lung cancer mortality in Shandong Province from 1970 to 2013. Lung cancer mortality data were obtained from Shandong Death Registration System and three nationwide retrospective cause-of-death surveys. A Purely Spatial Scan Statistics method with Discrete Poisson models was used to detect possible high-risk spatial clusters.
    [Show full text]